Raptor Pharmaceutical Corp. to Present at the 8th Annual BIO Investor Forum

NOVATO, California -

- Starting October 27th, the Company will use NASDAQ Ticker Symbol: RPTP

Raptor Pharmaceutical Corp. (Nasdaq: RPTP), today announced that senior management will present a corporate overview and update at the 8th Annual BIO Investor Forum, to be held October 28-29, 2009 at the Palace Hotel in San Francisco, CA. Raptor’s presentation will take place on Thursday, October 29 at 1:00pm in the Pacific Heights room.

(Logo: www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGO )

For more information on BIO Investor Forum conference please visit: investorforum.bio.org/opencms/bif/2009/index.jsp

Separately the company announced that as of Tuesday, October 27, Raptor will transition from its temporary NASDAQ ticker symbol, RPTPD, to the ticker symbol RPTP. Raptor was temporarily issued the NASDAQ ticker symbol RPTPD following the completion of its merger with TorreyPines Therapeutic which closed September 29, 2009.

About Raptor Pharmaceutical Corp.

Raptor Pharmaceutical Corp. (www.raptorpharma.com/index.htm) (Nasdaq: RPTP) (”Raptor”) is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Raptor focuses on underserved patient populations where it can have the greatest potential impact. Raptor currently has product candidates in clinical development designed to potentially treat nephropathic cystinosis (www.raptorpharma.com/patients_cystinosis.html), non-alcoholic steatohepatitis (”NASH”) (www.raptorpharma.com/patients_nash.html), Huntington’s Disease (”HD”) (www.raptorpharma.com/dr_cysteamine_huntingtons.html), aldehyde dehydrogenase (”ALDH2″) deficiency (www.raptorpharma.com/convivia.html), and a non-opioid solution (www.raptorpharma.com/tezampanel_migraine.html) designed to potentially treat chronic pain.

Raptor’s preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein (”RAP”) (www.raptorpharma.com/science_overview.html) and related proteins that are designed to target cancer, neurodegenerative disorders and infectious diseases.

For additional information, please visit www.raptorpharma.com.

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the following statements: Raptor’s ability to successfully develop any of its product candidates. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause the Company’s actual results to be materially different from these forward-looking statements. Factors which may significantly change or prevent the Company’s forward looking statements from fruition include that Raptor may be unsuccessful in developing any products or acquiring products; that Raptor’s technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; that Raptor is unable to retain or attract key employees whose knowledge is essential to the development of its products; that unforeseen scientific difficulties develop with the Company’s process; that Raptor’s patents are not sufficient to protect essential aspects of its technology; that competitors may invent better technology; that Raptor’s products may not work as well as hoped or worse, that the Company’s products may harm recipients; and that Raptor may not be able to raise sufficient funds for development or working capital. As well, Raptor’s products may never develop into useful products and even if they do, they may not be approved for sale to the public. Raptor cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company’s filings from time to time with the Securities and Exchange Commission (the “SEC”), which Raptor strongly urges you to read and consider, including the joint proxy statement/prospectus on Form S-4 filed with the SEC on August 19, 2009; Raptor’s annual report on Form 10-K filed with the SEC on March 27, 2009; Raptor’s quarterly report on Form 10-Q filed with the SEC on August 11, 2009; Raptor’s wholly-owned subsidiary’s, Raptor Pharmaceuticals Corp. (”RPC”) Registration Statement on Form S-1, as amended, that was declared effective on August 7, 2008; RPC’s annual report on Form 10-K filed with the SEC on October 30, 2008, as amended by that Form 10-K/A filed with the SEC on December 23, 2008; and RPC’s quarterly report on Form 10-Q filed with the SEC on July 15, 2009, all of which are available free of charge on the SEC’s web site at www.sec.gov. Subsequent written and oral forward-looking statements attributable to Raptor or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in Raptor’s reports filed with the SEC. Raptor expressly disclaims any intent or obligation to update any forward-looking statements.

For more information, please contact: Karl Cahill, Investor Relations +1-858-531-6100 kcahill@raptorpharma.com The Ruth Group Sara Ephraim Pellegrino (investors) +1-646-536-7002 spellegrino@theruthgroup.com Janine McCargo (media) +1-646-536-7033 jmccargo@theruthgroup.com

Source: Raptor Pharmaceutical Corp.

Karl Cahill, Investor Relations, +1-858-531-6100, kcahill at raptorpharma.com; or The Ruth Group, Sara Ephraim Pellegrino (investors), +1-646-536-7002, spellegrino at theruthgroup.com, or Janine McCargo (media), +1-646-536-7033, jmccargo at theruthgroup.com